Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Gross Margin (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Gross Margin readings, the most recent being 85.67% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 442.0% to 85.67% in Q4 2025 year-over-year; TTM through Dec 2025 was 88.5%, a 148.0% decrease, with the full-year FY2025 number at 88.5%, down 148.0% from a year prior.
  • Gross Margin hit 85.67% in Q4 2025 for Amicus Therapeutics, down from 88.49% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 91.95% in Q1 2023 to a low of 83.55% in Q3 2022.
  • Median Gross Margin over the past 5 years was 90.16% (2023), compared with a mean of 89.28%.
  • Biggest five-year swings in Gross Margin: soared 684bps in 2023 and later crashed -442bps in 2025.
  • Amicus Therapeutics' Gross Margin stood at 90.44% in 2021, then decreased by -1bps to 89.35% in 2022, then grew by 1bps to 90.16% in 2023, then fell by 0bps to 90.09% in 2024, then decreased by -5bps to 85.67% in 2025.
  • The last three reported values for Gross Margin were 85.67% (Q4 2025), 88.49% (Q3 2025), and 90.16% (Q2 2025) per Business Quant data.